Schonfeld Strategic Advisors’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-28,645
| Closed | -$1.13M | – | 2511 |
|
|
2023
Q2 | $1.13M | Sell |
28,645
-312,430
| -92% | -$11M | 0.01% | 936 |
|
|
2023
Q1 | $8.3M | Buy |
341,075
+75,541
| +28% | +$1.65M | 0.08% | 329 |
|
|
2022
Q4 | $5.69M | Buy |
265,534
+35,965
| +16% | +$768K | 0.05% | 445 |
|
|
2022
Q3 | $4.12M | Buy |
+229,569
| New | +$3.01M | 0.03% | 596 |
|
|
2022
Q1 | – | Sell |
-102,457
| Closed | -$1.71M | – | 3049 |
|
|
2021
Q4 | $1.71M | Sell |
102,457
-90,343
| -47% | -$1.48M | 0.02% | 745 |
|
|
2021
Q3 | $3.13M | Buy |
+192,800
| New | +$2.1M | 0.03% | 561 |
|
|
2020
Q4 | – | Sell |
-52,200
| Closed | -$295K | – | 1960 |
|
|
2020
Q3 | $295K | Buy |
52,200
+26,600
| +104% | +$127K | 0.01% | 1099 |
|
|
2020
Q2 | $131K | Sell |
25,600
-6,000
| -19% | -$25K | ﹤0.01% | 1156 |
|
|
2020
Q1 | $109K | Sell |
31,600
-80,300
| -72% | -$469K | 0.01% | 990 |
|
|
2019
Q4 | $960K | Buy |
+111,900
| New | +$400K | 0.02% | 521 |
|
|
2016
Q4 | – | Sell |
-10,248
| Closed | -$472K | – | 674 |
|
|
2016
Q3 | $472K | Buy |
10,248
+5,011
| +96% | +$283K | 0.08% | 273 |
|
|
2016
Q2 | $267K | Sell |
5,237
-11,818
| -69% | -$587K | 0.06% | 332 |
|
|
2016
Q1 | $721K | Buy |
+17,055
| New | +$869K | 0.29% | 95 |
|
Schonfeld Strategic Advisors's ISEE Position: Q3 2023 in Review
Schonfeld Strategic Advisors sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 28,645 shares — an estimated $1.13M sold.
Schonfeld Strategic Advisors first reported a position in ISEE in Q1 2016 and held it in 13 quarters. The position peaked at $8.3M in Q1 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Schonfeld Strategic Advisors reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 28,645 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $1.13M.
- Schonfeld Strategic Advisors first reported a position in IVERIC bio, Inc. Common Stock in Q1 2016 and held it in 13 quarters.
- Schonfeld Strategic Advisors's IVERIC bio, Inc. Common Stock position peaked at $8.3M in Q1 2023.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Schonfeld Strategic Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.